Trial Profile
A Single-blind, Randomized, Single-dose, Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of CJ-40001 and NESP® in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary) ; Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors CJ HealthCare; HK inno.N
- 01 Dec 2018 Results published in the BioDrugs
- 05 Jun 2018 New trial record